$CTGO
Contango ORE, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096321 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.795M $2.362M $2.510M
YoY Change 0.9% -5.89% 7.2%
% of Gross Profit
Research & Development $3.138M $163.9K $1.137M
YoY Change 159.32% -85.58% -74.86%
% of Gross Profit
Depreciation & Amortization $34.26K $26.99K $33.86K
YoY Change 31.78% -20.29% 6.51%
% of Gross Profit
Operating Expenses $2.795M $2.362M $3.681M
YoY Change -30.13% -35.82% -46.62%
Operating Profit $22.74M
YoY Change -336.5%
Interest Expense -$4.148M -$16.16M -$7.334M
YoY Change -54.66% 120.37% 2148.0%
% of Operating Profit -18.24%
Other Income/Expense, Net -$31.73M -$16.16M $606.5K
YoY Change 247.05% -2764.35% 1363.21%
Pretax Income -$8.994M -$18.55M -$10.42M
YoY Change -31.61% 78.06% 44.03%
Income Tax $718.8K $0.00
% Of Pretax Income
Net Earnings -$9.712M -$18.55M -$10.42M
YoY Change -26.14% 78.06% 44.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.81 -$1.90 -$1.38
Diluted Earnings Per Share -$0.81 -$1.90 -$1.38
COMMON SHARES
Basic Shares Outstanding 12.15M 9.632M 7.620M
Diluted Shares Outstanding 11.97M 9.776M 7.547M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.17M $24.12M $11.65M
YoY Change 95.38% 107.1% -49.57%
Cash & Equivalents $36.17M $24.12M $11.65M
Short-Term Investments
Other Short-Term Assets $1.319M $1.513M $644.9K
YoY Change -16.5% 134.62% -5.76%
Inventory
Prepaid Expenses $1.084M $1.279M $413.9K
Receivables
Other Receivables
Total Short-Term Assets $37.48M $25.63M $12.29M
YoY Change 86.65% 108.54% -48.31%
LONG-TERM ASSETS
Property, Plant & Equipment $52.49M $13.28M $13.37M
YoY Change 293.07% -0.69% -1.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.54M $54.47M $0.00
YoY Change 215.32%
Other Assets $120.8M $68.00M $13.37M
YoY Change 247.53% 408.57% -1.06%
Total Long-Term Assets $120.8M $68.00M $13.37M
YoY Change 247.53% 408.57% -1.06%
TOTAL ASSETS
Total Short-Term Assets $37.48M $25.63M $12.29M
Total Long-Term Assets $120.8M $68.00M $13.37M
Total Assets $158.3M $93.64M $25.66M
YoY Change 188.63% 264.87% -31.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.379M $790.6K $220.8K
YoY Change 11.71% 258.14% -65.17%
Accrued Expenses $12.23M $1.976M $2.078M
YoY Change 1302.72% -4.89% 138.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $34.90M $29.90M $0.00
YoY Change 1645.0%
Total Short-Term Liabilities $80.48M $50.54M $2.299M
YoY Change 1509.25% 2098.54% 52.75%
LONG-TERM LIABILITIES
Long-Term Debt $38.96M $44.70M $25.46M
YoY Change 18.59% 75.58% 32.31%
Other Long-Term Liabilities $46.78M $36.28M $2.681M
YoY Change 684.85% 1253.48% -18.16%
Total Long-Term Liabilities $88.07M $80.98M $28.14M
YoY Change 126.9% 187.8% 24.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $80.48M $50.54M $2.299M
Total Long-Term Liabilities $88.07M $80.98M $28.14M
Total Liabilities $168.5M $131.5M $30.44M
YoY Change 284.69% 332.1% 26.71%
SHAREHOLDERS EQUITY
Retained Earnings -$187.8M -$178.1M -$98.28M
YoY Change 68.54% 81.21% 67.89%
Common Stock $177.6M $140.3M $93.50M
YoY Change 45.02% 50.0% 26.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.22M -$37.88M -$4.773M
YoY Change
Total Liabilities & Shareholders Equity $158.3M $93.64M $25.66M
YoY Change 188.63% 264.87% -31.19%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$9.712M -$18.55M -$10.42M
YoY Change -26.14% 78.06% 44.03%
Depreciation, Depletion And Amortization $34.26K $26.99K $33.86K
YoY Change 31.78% -20.29% 6.51%
Cash From Operating Activities $17.49M -$2.441M -$1.106M
YoY Change -592.52% 120.69% -76.45%
INVESTING ACTIVITIES
Capital Expenditures $35.17K -$330.00 $0.00
YoY Change 402.79%
Acquisitions
YoY Change
Other Investing Activities -$4.632M -$11.79M -$6.720M
YoY Change -82.86% 75.45%
Cash From Investing Activities -$4.668M -$11.79M -$6.720M
YoY Change -82.74% 75.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -779.2K 30.73M 16.55M
YoY Change -102.08% 85.66% -16.42%
NET CHANGE
Cash From Operating Activities 17.49M -2.441M -1.106M
Cash From Investing Activities -4.668M -11.79M -6.720M
Cash From Financing Activities -779.2K 30.73M 16.55M
Net Change In Cash 12.05M 16.50M 8.727M
YoY Change 75.59% 89.08% -42.24%
FREE CASH FLOW
Cash From Operating Activities $17.49M -$2.441M -$1.106M
Capital Expenditures $35.17K -$330.00 $0.00
Free Cash Flow $17.46M -$2.441M -$1.106M
YoY Change -590.56% 120.66% -76.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001502377
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 ctgo Rights Agreement Number Of Preferred Stock Issuable Per Right
RightsAgreementNumberOfPreferredStockIssuablePerRight
0.001
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35770
dei Entity Registrant Name
EntityRegistrantName
CONTANGO ORE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3431051
dei Entity Address Address Line1
EntityAddressAddressLine1
516 2nd Avenue, Suite 401
dei Entity Address City Or Town
EntityAddressCityOrTown
Fairbanks
dei Entity Address State Or Province
EntityAddressStateOrProvince
AK
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
99701
dei City Area Code
CityAreaCode
907
dei Local Phone Number
LocalPhoneNumber
888-4273
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.01 per share
dei Trading Symbol
TradingSymbol
CTGO
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12145408
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24118918
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15504819
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
234433
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
232572
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1278663
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1112910
CY2024Q2 us-gaap Assets Current
AssetsCurrent
25632014
CY2023Q4 us-gaap Assets Current
AssetsCurrent
16850301
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
54468519
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
28064405
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13279522
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13326347
CY2024Q2 ctgo Commitment Fee
CommitmentFee
255517
CY2023Q4 ctgo Commitment Fee
CommitmentFee
350575
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68003558
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41741327
CY2024Q2 us-gaap Assets
Assets
93635572
CY2023Q4 us-gaap Assets
Assets
58591628
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
790613
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
250739
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1976353
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2241087
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17869326
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2679784
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
29900000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7900000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
50536292
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13071610
CY2024Q2 ctgo Advance Royalty Reimbursement Noncurrent
AdvanceRoyaltyReimbursementNoncurrent
1200000
CY2023Q4 ctgo Advance Royalty Reimbursement Noncurrent
AdvanceRoyaltyReimbursementNoncurrent
1200000
CY2024Q2 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
252547
CY2023Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
246227
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1100480
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1100480
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
33727276
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20737997
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
44698449
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36779859
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
80978752
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
60064563
CY2024Q2 us-gaap Liabilities
Liabilities
131515044
CY2023Q4 us-gaap Liabilities
Liabilities
73136173
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10365914
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10363434
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9454233
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9451753
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
103658
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
94542
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
140150016
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124451067
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2480
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2480
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
48308
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
48308
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178084838
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139041846
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-37879472
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-14544545
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
93635572
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58591628
CY2024Q2 ctgo Claim Rental Expense
ClaimRentalExpense
128117
CY2023Q2 ctgo Claim Rental Expense
ClaimRentalExpense
126451
ctgo Claim Rental Expense
ClaimRentalExpense
256234
ctgo Claim Rental Expense
ClaimRentalExpense
252903
CY2024Q2 us-gaap Exploration Expense
ExplorationExpense
35788
CY2023Q2 us-gaap Exploration Expense
ExplorationExpense
1010453
us-gaap Exploration Expense
ExplorationExpense
122432
us-gaap Exploration Expense
ExplorationExpense
1262380
CY2024Q2 us-gaap Depreciation Nonproduction
DepreciationNonproduction
26996
CY2023Q2 us-gaap Depreciation Nonproduction
DepreciationNonproduction
33859
us-gaap Depreciation Nonproduction
DepreciationNonproduction
53992
us-gaap Depreciation Nonproduction
DepreciationNonproduction
68073
CY2024Q2 us-gaap Accretion Expense
AccretionExpense
3181
CY2023Q2 us-gaap Accretion Expense
AccretionExpense
3021
us-gaap Accretion Expense
AccretionExpense
6321
us-gaap Accretion Expense
AccretionExpense
5886
CY2024Q2 ctgo Impairment From Casualty Loss
ImpairmentFromCasualtyLoss
-0
CY2023Q2 ctgo Impairment From Casualty Loss
ImpairmentFromCasualtyLoss
7111
ctgo Impairment From Casualty Loss
ImpairmentFromCasualtyLoss
-0
ctgo Impairment From Casualty Loss
ImpairmentFromCasualtyLoss
7111
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2192406
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2510042
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4660401
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4490963
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
2386488
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
3690937
us-gaap Costs And Expenses
CostsAndExpenses
5099380
us-gaap Costs And Expenses
CostsAndExpenses
6087316
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
10409
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4905
us-gaap Investment Income Interest
InvestmentIncomeInterest
22459
us-gaap Investment Income Interest
InvestmentIncomeInterest
13307
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2920550
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-615979
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-4951364
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1063489
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-695633
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-6720000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-835886
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-11810000
CY2024Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-12553491
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-28178821
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
CY2024Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
606499
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
606499
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16159265
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6724575
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33943612
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12253683
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-18545753
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10415512
us-gaap Net Income Loss
NetIncomeLoss
-39042992
us-gaap Net Income Loss
NetIncomeLoss
-18340999
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9775758
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9775758
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7547472
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7547472
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9681064
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9681064
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7455691
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7455691
us-gaap Net Income Loss
NetIncomeLoss
-39042992
us-gaap Net Income Loss
NetIncomeLoss
-18340999
us-gaap Share Based Compensation
ShareBasedCompensation
1312179
us-gaap Share Based Compensation
ShareBasedCompensation
1332867
us-gaap Depreciation
Depreciation
53992
us-gaap Depreciation
Depreciation
68073
us-gaap Accretion Expense
AccretionExpense
6321
us-gaap Accretion Expense
AccretionExpense
5886
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
7111
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-835886
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-11810000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-28178821
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
us-gaap Paid In Kind Interest
PaidInKindInterest
200048
us-gaap Paid In Kind Interest
PaidInKindInterest
438877
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-606500
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1491227
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
-144689
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
165753
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-402689
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
275128
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
893831
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6855143
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4132854
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
27240000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
11810000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
719
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7167
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27247167
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11810719
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
39496
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6886000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
30000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7647500
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1477569
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1634973
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14195839
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5965582
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42718270
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18824613
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8615960
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2881040
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15737391
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8996154
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24353351
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11877194
us-gaap Interest Paid Net
InterestPaidNet
2762152
us-gaap Interest Paid Net
InterestPaidNet
607787
ctgo Commitment Fee Derecognized And Added To Debt Discount
CommitmentFeeDerecognizedAndAddedToDebtDiscount
453124
ctgo Commitment Fee Derecognized And Added To Debt Discount
CommitmentFeeDerecognizedAndAddedToDebtDiscount
0
ctgo Fair Value Of Investing Activities Assumed
FairValueOfInvestingActivitiesAssumed
453124
ctgo Fair Value Of Investing Activities Assumed
FairValueOfInvestingActivitiesAssumed
0
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-34049820
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
641554
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13118127
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1290352
CY2024Q2 ctgo Stock Issued During Period Value Warrants Issuance
StockIssuedDuringPeriodValueWarrantsIssuance
2146722
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
100050
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-18545753
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-37879472
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5723550
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
725049
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4205191
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
550609
CY2023Q2 ctgo Stock Issued During Period Shares Treasury Stock Reissued Value
StockIssuedDuringPeriodSharesTreasuryStockReissuedValue
-138871
CY2023Q2 ctgo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5858772
CY2023Q2 ctgo Stock Issued During Period Value Warrant Modification
StockIssuedDuringPeriodValueWarrantModification
-382769
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1409997
CY2023Q2 ctgo Stock Issued During Period Shares Treasury Stock Issued For Convertible Note Interest Payment
StockIssuedDuringPeriodSharesTreasuryStockIssuedForConvertibleNoteInterestPayment
100000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
338879
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
15
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10415512
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4773438
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-14544545
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1312179
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13345726
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1296610
ctgo Stock Issued During Period Value Warrants Issuance
StockIssuedDuringPeriodValueWarrantsIssuance
2146722
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
200048
us-gaap Net Income Loss
NetIncomeLoss
-39042992
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-37879472
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-777383
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1332867
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6077528
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
589609
ctgo Stock Issued During Period Shares Treasury Stock Reissued Value
StockIssuedDuringPeriodSharesTreasuryStockReissuedValue
39481
ctgo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5858772
ctgo Stock Issued During Period Value Warrant Modification
StockIssuedDuringPeriodValueWarrantModification
-382769
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1848179
ctgo Stock Issued During Period Shares Treasury Stock Issued For Convertible Note Interest Payment
StockIssuedDuringPeriodSharesTreasuryStockIssuedForConvertibleNoteInterestPayment
238886
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
438877
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
39496
us-gaap Net Income Loss
NetIncomeLoss
-18340999
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4773438
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Basis of Presentation</span></p><p id="led470819f20239231698094677203" style="text-indent:4.44%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), including instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by US GAAP for complete annual consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated financial statements have been included. All such adjustments are of a normal recurring nature. The consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes included in the Company’s Form 10-KT for the six-month period ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">D</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ecember 31, 2023 and its Form 10-K for the fiscal year ended June 30, 2023. The results of operations for the </span><span id="led470819f20239231698093792607"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024.</span></p>
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1278663
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1112910
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18545753
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9775758
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.9
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10415512
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7547472
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18545753
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9775758
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.9
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10415512
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7547472
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39042992
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9681064
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.03
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18340999
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7455691
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-39042992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9681064
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.03
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18340999
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7455691
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
866875
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
866875
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
501000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
501000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
429153
CY2024Q2 ctgo Sharebased Compensation Arrangement By Sharebased Payment Award Options And Warrants Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndWarrantsOutstandingNumber
866875
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 ctgo Rights Agreement Exercise Price
RightsAgreementExercisePrice
100
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
298856
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
244864
us-gaap Asset Impairment Charges
AssetImpairmentCharges
122136
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
122136
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13279522
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13326347
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
100000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1300000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y6M21D
CY2019Q1 ctgo Contingent Salary And Compensation Retention Agreement
ContingentSalaryAndCompensationRetentionAgreement
1000000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
ctgo Percentage Of Taxable Income To Nols
PercentageOfTaxableIncomeToNols
0.80
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
74598449
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
44679859
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
29900000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7900000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
44698449
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36779859
CY2024Q2 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-51596602
CY2024Q2 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-51596602
CY2024Q2 us-gaap Marketing Expense
MarketingExpense
169904
CY2023Q2 us-gaap Marketing Expense
MarketingExpense
58866
us-gaap Marketing Expense
MarketingExpense
250899
us-gaap Marketing Expense
MarketingExpense
181359
CY2024Q2 ctgo Office And Administrative Costs
OfficeAndAdministrativeCosts
52506
CY2023Q2 ctgo Office And Administrative Costs
OfficeAndAdministrativeCosts
72819
ctgo Office And Administrative Costs
OfficeAndAdministrativeCosts
115049
ctgo Office And Administrative Costs
OfficeAndAdministrativeCosts
146543
CY2024Q2 us-gaap Insurance Tax
InsuranceTax
286010
CY2023Q2 us-gaap Insurance Tax
InsuranceTax
267921
us-gaap Insurance Tax
InsuranceTax
609176
us-gaap Insurance Tax
InsuranceTax
490376
CY2024Q2 us-gaap Professional Fees
ProfessionalFees
286804
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
623519
us-gaap Professional Fees
ProfessionalFees
705612
us-gaap Professional Fees
ProfessionalFees
791579
CY2024Q2 ctgo Regulatory Fees
RegulatoryFees
76389
CY2023Q2 ctgo Regulatory Fees
RegulatoryFees
93162
ctgo Regulatory Fees
RegulatoryFees
184282
ctgo Regulatory Fees
RegulatoryFees
172592
CY2024Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
433385
CY2023Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
439234
us-gaap Labor And Related Expense
LaborAndRelatedExpense
996529
us-gaap Labor And Related Expense
LaborAndRelatedExpense
921688
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
641554
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
725049
us-gaap Share Based Compensation
ShareBasedCompensation
1312179
us-gaap Share Based Compensation
ShareBasedCompensation
1332867
CY2024Q2 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
95854
CY2023Q2 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
58222
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
186675
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
97709
CY2024Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
150000
CY2023Q2 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
171250
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
300000
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
356250
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2192406
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2510042
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4660401
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4490963

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-096321-index-headers.html Edgar Link pending
0000950170-24-096321-index.html Edgar Link pending
0000950170-24-096321.txt Edgar Link pending
0000950170-24-096321-xbrl.zip Edgar Link pending
ctgo-20240630.htm Edgar Link pending
ctgo-20240630.xsd Edgar Link pending
ctgo-ex10_1.htm Edgar Link pending
ctgo-ex10_2.htm Edgar Link pending
ctgo-ex31_1.htm Edgar Link pending
ctgo-ex31_2.htm Edgar Link pending
ctgo-ex32_1.htm Edgar Link pending
ctgo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
ctgo-20240630_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending